News

Continuous delivery of carbidopa/levodopa (CD/LD) with ND0612 under the skin led to quick improvement of clinical status and better quality of life for  patients with advanced Parkinson’s disease, according to patient-reported outcomes from a Phase 2 clinical trial. Now, a global Phase 3 study named BouNDless (NCT04006210) is…

With the aim of opening entirely new avenues in Parkinson’s disease research and care, The Michael J. Fox Foundation (MJFF) has announced a $10 million contest to drive development of an imaging tracer that would be used to see alpha-synuclein protein in the living brain. Called the “…

The small molecule IRL752 may be a safe and effective treatment, which could potentially help manage symptoms known to be unresponsive to levodopa, for people with Parkinson’s disease dementia, results from a Phase 2a clinical study suggest. Preliminary data suggests treatment with IRL752 could reduce apathy, as…

Gocovri (amantadine) extended release capsules work to help lessen dyskinesia, or involuntary muscle movement, and off episodes in Parkinson’s, but special care needs to be given elderly patients with poorer kidney function, according to data presented by Adamas Pharmaceuticals, the treatment’s developer, at a science conference. Renal…

A Phase 2 clinical trial testing the safety and effectiveness of the gene therapy VY-AADC02 in people with advanced Parkinson’s disease is recruiting patients at select sites across the U.S., according to a release by one such site. Hackensack University Medical Center is among the 17 institutions across…

People with Parkinson’s disease who have a specific mutation in the LRRK2 gene may be 10 times more likely to develop leukemia, and twice as likely to have colon cancer, researchers report. The researchers say this particular patient population should be closely monitored and screened for the early…

People taking Hytrin (terazosin) or similar medications to treat high blood pressure and benign prostatic hyperplasia may be less likely to develop Parkinson’s disease, an early study suggests. Parkinson’s patients who use these medications may also see their disease progress more slowly and with fewer complications, its researchers report.

Use of Inbrija (levodopa inhalation powder) helps to effectively manage off episodes in Parkinson’s disease without an increase in troublesome dyskinesia, or involuntary muscle movement, according to data being presented by Acorda Therapeutics at the International Congress of Parkinson’s Disease and Movement Disorders. Results from…

The National Institute of Neurological Disorders and Stroke, of the National Institute of Health (NIH), has awarded a large grant to researchers who are seeking to understand the molecular structure of toxic proteins that drive brain disorders. Irregular clumps of certain proteins are thought to be the…

The National Science Foundation (NSF) has awarded a University of Rhode Island (URI) professor nearly $250,000 to help commercialize a “smart glove” for Parkinson’s disease patients. Kunal Mankodiya, PhD, an associate professor of engineering, is developing the glove that can capture wearers’ movement data. Designed for those with PD…